MATERIALS AND METHODS
Between 2002 and 2010, 18 consecutive female patients with acute or subacute iliofemoral deep vein thrombosis in the postpartum period who had endovascular treatment were retrospectively evaluated. Treatment consisted of manual aspiration thrombectomy with or without catheter-directed thrombolysis. Stents were placed in the iliac veins, if deemed necessary. Clot removal was graded as complete (>95%), partial (50%-95%), and poor (<50%).
RESULTS
The initial treatment was technically successful in 17 patients (94%). There was complete clot removal in 15 of 22 limbs (68%). Twenty-three stents were implanted in 15 patients (83%). The primary and secondary patencies were 58% and 82% at one year, 58% and 72% at three years, and 58% and 58% at ve years, respectively. There were recurrent thromboses in 11 patients (61%), which occurred within the rst month in nine of these patients (81%). Ten patients had repeated intervention, and ve had successful outcomes. At a mean follow-up of 30 months, 11 patients had uninterrupted in-line ow in the affected limb, and six patients did not. Six of the patients with uninterrupted ow were asymptomatic, and ve patients had minimal swelling at the ankle.
CONCLUSION Endovascular treatment of postpartum iliofemoral deep vein thrombosis with percutaneous aspiration thrombectomy alone or combined with catheter-directed thrombolysis and iliac vein stenting is an effective therapy resulting in a high rate of thrombus removal. However, recurrences are high, particularly in the rst post-intervention month. Frequent patient followup in the rst post-intervention month is necessary. 
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The DVT risk factor for all of the included patients was being in the postpartum period. The additional risk factors involved were a documented thrombophilic disorder in five patients (28%) and femoral vein catheterization in one patient (5.6%).
Endovascular procedure
All patients were informed about the endovascular treatment, which is the treatment of choice for acute and subacute iliofemoral DVT at our hospital. Written informed consent was obtained after explaining the advantages and risks of the procedure. Heparin was administered at a therapeutic dose during all procedures beginning at the start of the procedure. A target activated prothrombin time of 60 to 90 s was regarded as therapeutic. The procedure was carried out with local anesthesia in all patients with intravenous sedoanalgesia using midazolam and fentanyl with continuous monitoring, if needed.
In the early period of the study, catheter-directed thrombolysis (CDT) was the first-line of treatment, whereas manual aspiration thrombectomy (MAT) became the first-line of treatment later on. Two patients underwent CDT as the first-line thrombus removal method, and four patients who had a residual thrombus after MAT required CDT. The total treatment time ranged from 1 to 5 days (mean, 1.5 days). The MAT became the first-line treatment method after the first two patients. Patients were placed prone on the angiography table (Innova IQ3100, GE Healthcare, Waukesha, Wisconsin, USA). Endovascular access was established using ultrasonography-guided puncture of the ipsilateral popliteal vein with a 21 G or 18 G needle in all patients. The posterior tibial vein was additionally accessed in two patients. A 4 F plastic dilator was introduced into the vein initially, and ascending venography was performed. A 9 F or 10 F vascular sheath (Avanti, Cordis Europa NV, Roden, The Netherlands) was then placed after the removal of the dilator over a guide wire. Thrombus removal was performed by MAT using 8 F or 9 F guiding catheters (Cordis Europa NV) connected to a 20 mL syringe or CDT. CDT was usually adjunctively used to treat the residual thrombus or to treat crural vein thrombosis. Tissue plasminogen activator (tPA) (Actilyse, Boehringer Ingelheim, Rhein, Germany) was administered through a multi-sidehole infusion catheter (ev3, Irvine, California, USA) at a dose of 1 mg/hour. Venography was repeated every 8-12 hours during thrombolysis until the entire thrombus was resolved or there was no more lysis with CDT. After thrombus removal with MAT or CDT, additional pelvic venograms were obtained for a detailed evaluation of the iliac veins during the procedure. One or more self-expanding stents were placed in the iliac veins if there was May-Thurner (iliac vein compression) syndrome, irregularity due to a residual thrombus, or severe stenosis of the iliac vein limiting blood flow. Twenty-one stents were self-expanding Wallstents (Boston Scientific, Natick, Massachusetts, USA), and two were self-expanding nitinol stents (Protege, ev3, Plymouth, Minnesota, USA). If there was chronic occlusion due to iliac vein compression, a hydrophilic guide wire was subacute iliofemoral DVT were treated by endovascular methods. The postpartum period was defined as the first 42 days (six weeks) after childbirth. All data were analyzed retrospectively. Fourteen of these patients were among 139 consecutive patients with acute or subacute iliofemoral DVT treated by endovascular methods at our institution. All patients with iliofemoral DVT were treated with endovascular methods per the routine protocol at our institution in the absence of contraindications.
The mean age of patients was 28±5.6 years (range, 20-42 years) (Table) . All patients had iliofemoral DVT diagnosed with color Doppler ultrasonography (CDUS) and confirmed with venography at the time of the intervention. The exclusion criteria were distal (femoropopliteal) DVT, contraindications to iodinated contrast media, and malignancy with short survival expectancy. No patients met these criteria during the study period. 
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passed through the occlusion (Terumo Europe, Leuven, Belgium), and one or more self-expanding stents were placed. The stent was always dilated with a balloon catheter of the same diameter as the stent (Ultrathin, Boston Scientific, Galway, Ireland).
The patients were discharged on the same day or the first post-procedural day. Patients were put on oral warfarin sodium therapy and maintained on an international normalized ratio in the range of 2.0-3.0 for at least six months after the procedure. The administration of anticoagulation was bridged with low molecular weight heparin when switching from intravenous heparin to oral warfarin. Graduated compressive stockings were recommended to all patients.
Data collection
Data concerning the demographics, past medical histories, and laboratory findings were evaluated retrospectively. Venography findings were analyzed using images stored on digital media. Real-time examinations and the interpretation of venography findings were performed by the same interventional radiologist (L.O.).
Definition of criteria, outcomes, and follow-up
May-Thurner syndrome was defined as severe compression causing intimal changes in the lumen of the left common iliac vein by the overlying artery (9) . Mild compression of the vein that did not cause significant narrowing of the lumen with normal venous intima was not regarded as the syndrome but as mild compression.
Definitions of criteria were based on the guidelines concerning lower extremity DVT defined by the Society of Interventional Radiology (10). Technical success was defined as the successful restoration of antegrade inline flow in the treated vein with the elimination of any underlying obstructive lesion and was assessed on the final procedural venogram. Clot removal was regarded as complete (grade III) if clot removal was >95%, partial (grade II) if clot removal was between 50%-95%, and poor (grade I) if clot removal was <50% in the popliteal femoroiliac axis, including the inferior vena cava (IVC).
Each patient was followed during regular outpatient visits at 1, 3, 6, and 12 months and then annually for five years. At each clinical visit, a clinical examination for symptoms and CEAP (Clinical-Etiology-AnatomicPathophysiologic) score and CDUS for venous patency and insufficiency were performed. Venography was recommended at one or three years of followup or if the clinical or CDUS findings indicated potential occlusion of the iliac vein. The patients were recalled after the study ended, their latest CEAP scores were obtained, and the presence of the iliac, femoral, popliteal, and greater saphenous veins was examined using CDUS.
Statistical analysis
Data are expressed as the mean±standard deviation for continuous variables and percentages for categorical variables. Patency at the end of the follow-up was analyzed using a Kaplan-Meier analysis. Statistical analyses were performed using a computer software (Statistical Package for Social Sciences version 11.0, SPSS Inc., Chicago, Illinois, USA).
Results
Short-term results
All patients were symptomatic and had leg swelling; nine patients (50%) had pain, three patients (17%) had phlegmasia cerulea alba, and none had phlegmasia cerulea dolens. DVT was acute (1-14 days) in 13 patients (72%), subacute (15-28 days) in three patients (17%) and acute with underlying chronic DVT in two patients. DVT was bilateral in four patients, left sided in 12 patients (72%), and right sided in two patients (12%). The popliteal and crural veins were patent in seven patients (39%) with thrombosis of the proximal femoral vein, common femoral vein and iliac veins. The popliteal vein and its distal tributaries were patent in the latter group. Therefore, six patients had involvement of the iliac and femoral veins, and 12 patients had involvement of the iliac, femoral, popliteal, and crural veins. Five of these 12 patients also had IVC involvement. Three patients had pulmonary thromboemboli at the time of diagnosis (17%). None of the patients had a pulmonary embolism during or after the intervention at a mean of 30 months of follow-up. Eleven of 18 patients (61%) had iliac vein compression syndrome (May-Thurner syndrome).
Three
Catheter-directed thrombolytic therapy was used in only six patients. The mean dose of tPA was 30±27.4 mg (range, 10-70 mg). The mean fluoroscopy time was 14±8.6 min (range, 4-25 min). One patient had prophylactic retrievable IVC filter placement because of a large, free-floating thrombus in the IVC. The filter was removed on the second day. After removal of the thrombus using MAT or CDT (Fig. 1) , a total of 23 stents were implanted in 15 patients (83%), with an average of 1.5 stents per extremity (Fig. 2) . Stents were implanted in the common iliac vein (n=8), the common and external iliac veins (n=7), and from the external iliac vein to the femoral vein (n=8). The stent diameters ranged from 12 to 16 mm. None of our patients had pulmonary thromboemboli during the procedure. There were three complications during the initial treatment procedures. Two were minor dissections in the vein that did not interrupt flow. The third complication was an in-stent thrombosis that was successfully treated during the same session.
The initial treatment was technically successful in 17 patients, with a technical success rate of 94% (21 of 22 extremities). There was complete clot removal in 15 of 22 limbs (68%), partial clot removal in six limbs (27%) and poor clot removal (technical failure) in one limb. Immediate venous patency with normal in-line flow was achieved in 17 of 18 patients and 21 of 22 limbs.
Long-term results
The mean follow-up was 30±27 months (range, 3-96 months). One patient was lost to follow-up. All of the patients underwent a CDUS examination, and 11 patients underwent venography during the follow-up. Three patients were followed for longer than five years. A Kaplan-Meier analysis revealed that primary limb patency was 58% at one year, three years, and five years. The secondary limb patencies were 82% at one year, 72% at three years, and 58% at five years.
Eleven patients (61%) had a recurrence of thrombosis (Fig. 3) . However, the two patients who had acute DVT with underlying chronic DVT did not experience a recurrence. Recurrences occurred in the first month in nine patients (50%), in the second month in one patient, and in the 34th month in one patient; 70% of the recurrent thromboses occurred within the first 10 days. There were no other recurrences after a mean follow-up of 30 months. One patient had very mild symptoms, and a second intervention was not needed. Ten patients underwent a second intervention. Repeated intervention established in-line venous flow in five patients but was unsuccessful in the remaining five patients. The reasons for treatment failure included immediate recurrent thrombosis despite successful endovascular recanalization in two patients, recurrent thrombosis 15 days after successful endovascular recanalization in one patient, and an inability to recanalize the occluded stent in two patients. All patients were maintained at international normalized ratio (INR) of 2.0 to 3.0 immediately after the intervention. The same techniques used for primary intervention were applied in the repeated interventions. Six patients (33%) who required repeated intervention had a grade III removal with more than 95% clearance (complete removal) in the primary intervention. Four (22%) of the patients who required repeated intervention had a grade II removal with less than a 95% clearance rate in the primary intervention. In the postpartum group, we encountered no contralateral DVT in patients who had stent implantation in the ipsilateral common iliac vein.
At the mean follow-up of 30 months, 11 patients had uninterrupted flow in the limb, and six patients did not. Six of the patients with uninterrupted flow were asymptomatic, and five had minimal swelling at the ankle at a mean follow-up of 30 months. The six patients with occluded veins at the end of the follow-up had mild to moderate symptoms consistent with post-thrombotic syndrome including swelling around the ankle and pigmentation of the medial malleolar region (CEAP 3 and 4) . None of the patients developed ulceration (CEAP 5 and 6) during follow-up.
Results after reappraisal
All patients were recalled for a repeat examination to determine their latest CEAP scores and evaluate the presence of the iliac, femoral, popliteal, and greater saphenous veins using CDUS.
Six patients (33%) were asymptomatic, and 12 patients (67%) were symptomatic. Six patients had swelling and heaviness, five patients (28%) had swelling, one patient (8%) had pruritus, and one (8%) had pain and fatigue upon walking. The patients were classified as CEAP 0 (n=5), CEAP 1 (n=3), CEAP 2 (n=5), CEAP 3 (n=3), and CEAP 4 (n=2) in the reappraisal. Therefore, 13 of the 18 patients (72%) were CEAP 0-2.
Venous insufficiency was present in nine patients; five of six patients (80%) with occluded veins had venous insufficiency, whereas five of 12 patients (42%) with patent veins had venous insufficiency.
Discussion
The current study showed that, in patients with iliofemoral DVT, there was frequent involvement of the IVC and a high incidence of May-Thurner syndrome (92% in left-sided DVT patients). The distal veins were patent in a high number of patients (39% of patients), indicating that DVT started proximally and extended distally. This is a rare occurrence in patients with DVT in the general population (11) . Complete or near-complete thrombus removal was achieved in all but one patient. Although the technical success was very high, recurrences were also high. Most recurrences occurred in the first month following the intervention while the patient was receiving therapeutic-level anticoagulation. There was no clear explanation for the recurrences. There was little problem with residual thrombi because most patients had nearly all of the thrombus removed by the endovascular methods. Hormonal factors alone and hormone-induced thrombophilia might play a role in the early recurrence of iliofemoral DVT after endovascular intervention as the hypercoagulable state of pregnancy continues in the postpartum period and does not return to normal until more than eight weeks postpartum (12) . A high rate of early recurrent thrombosis can be managed by rigorous anticoagulant administration and the frequent CDUS examination of all patients in the first postprocedural month. If recurrences can be detected very early in the immediate postprocedural period, repeated interventions might be effective at preventing further thromboses. If early recurrent thromboses can be prevented in the first month after the initial procedure, good long-term results can be expected.
DVT commonly causes morbidity and mortality with serious short-and long-term medical, social, and economic consequences for patients (2) . The primary aims of treatment for postpartum DVT are to restore vessel patency by removing the thrombus and alleviating the acute symptoms to prevent recurrent thrombosis and pulmonary embolism and to preserve venous valve function and thereby prevent post-thrombotic syndrome (13) . Systemic anticoagulation therapy is the standard treatment for acute or subacute DVT (14) . Anticoagulation does not cause lysis of the present thrombus but prevents new clot formation. It has proven to be efficient for the prevention of pulmonary embolism and recurrent thrombosis but has not been associated with fast symptom relief or recanalization of the thrombotic vessel. Akesson (15) showed that 95% of patients with iliofemoral DVT treated with anticoagulation alone had ambulatory venous hypertension at five years and 90% of patients had chronic venous insufficiency. Plate et al. (13) reported that 71% of medically treated patients developed leg swelling and 17% developed leg ulcers within a 10-year follow-up period. Plate et al. (13) also reported that 59% of medically treated patients had occluded iliac veins. Nazir et al. (14) demonstrated that, in over 50% of medically treated patients, there was a failure of complete thrombus removal. Although these outcomes are generally consistent in all venous segments, iliofemoral obstruction leads to the most significant morbidity (2) . Iliofemoral obstruction eventually leads to a decreased quality of life for the patient. Therefore, it is important to provide early treatment to re-establish a patent venous system.
The overall prevalence of thromboembolic events is increased in pregnant women and is approximately two per 100 deliveries, 80% of which are venous in origin (16) . Moreover, the risk of DVT is 20-80-fold higher in the postpartum period when compared to pregnancy (12) . In the first week of the postpartum period, the risk is 100-fold higher (12) . One of the reasons for the increased risk of DVT during the third trimester and shortly after delivery is most likely due to the obstruction of the left common iliac vein by the enlarged uterus in addition to the hypercoagulability generated by pregnancy (16) . A subsequent pulmonary embolism is one of the most common causes of maternal mortality (3) . One third of pregnancy-related DVTs and 50% of pregnancy-related pulmonary embolisms occur postpartum (16) . Iliofemoral DVT is common during and after pregnancy, and the anatomic distribution of these lesions varies significantly from nonpregnant women (11) . Thromboses originating in the pelvic veins account for less than 1% of all DVTs in the normal population. In contrast, venous thromboses in the postpartum period usually originate in the pelvic veins rather than the calf veins (11, 16) . Chan et al. (11) reported that 64% of DVTs in pregnant women were restricted to the iliac and/or femoral vein in a survey of medical reports after a systematic review.
Alternative treatment approaches, such as endovascular methods have become more widely used due to the somewhat disappointing outcomes following standard anticoagulation therapy. Catheter-directed thrombolysis has become the most commonly used endovascular thrombus treatment method. The most important drawbacks of CDT are the lengthy infusion times and bleeding complications (17) . Laiho et al. (18) reported that valvular competence was preserved in up to 44% of patients who were treated with CDT. A similar favorable outlook has been presented in a report by Sillesen et al., (19) who noted that, after an average follow-up of 24 months, iliofemoral DVT patients treated by CDT had no recurrent thromboses. Catheterdirected endovascular treatment is more effective at improving patient symptoms and removing thrombi than anticoagulant therapy alone (3, 20, 21) . Other endovascular methods include MAT, during which the thrombus is aspirated through large-bore (7 F to 9 F) guiding catheters, and percutaneous mechanical thrombectomy, during which a mechanical device causes microfragmentation of the thrombus followed by aspiration or lysis of the clot in the vessel. These procedures are able to more rapidly clear the thrombus and also decrease the risk of bleeding complications. The aspiration thrombectomy method is a cheap and simple method (22, 23) . This method has been successfully used in arterial and graft occlusions (24, 25) . This method also decreases post-thrombotic morbidity and improves quality of life (19, 26) . Aspiration thrombectomy has the advantage of being able to be used in every patient, including those who cannot receive anticoagulants, those who develop complications during anticoagulation therapy, and those with a contraindication to thrombolytic administration (27) .
Compared with patients treated with heparin and oral warfarin, the length of hospital stay and subsequent economic burden are decreased overall because, as reported by Jackson et al., (20) most of the patients who were given MAT and CDT therapy were discharged without an overnight hospital stay or within 24 hours. Our average hospital stay time was 1.6 days per patient. Post-thrombotic syndrome, which is the most important late complication of DVT, has been reported to occur in 29%-79% of acute cases (8) . The reported complications of MAT and CDT are hemorrhage, pulmonary embolism, and death (2). In the report by Camerota and Gravett (2), it was found that major bleeding complications occurred after CDT in approximately 5%-10% of the patients. No such complications occurred in this study. In the current study, there was no mortality, and no bleeding occurred. There was only one major complication in the initial treatment. which was an acute in-stent thrombosis. We observed no pulmonary embolism. The absence of post-procedural pulmonary embolism improves the long-term outcome. Although the number of patients in this study was limited, these findings confirm our belief that MTA combined with CDT and stent placement is a safe procedure.
There are limitations of the study. The retrospective nature of this study is one of these limitations. We did not obtain data on quality of life, which is an important long-term factor. Additionally, measuring the levels of hormonal factors or inflammatory markers would have added to the study but could not be performed because this was a retrospective study, and we were unaware of the high recurrence rate among postpartum patients at the outset of the study. All patients were maintained at INR levels of 2.0 to 3.0 immediately after the intervention as explained in the methods section. However, despite frequent INR testing, some patients' INR levels might have remained lower than planned, causing thrombosis recurrence. Unfortunately, we cannot determine whether this occurred due to the intermittent nature of INR testing, which is an inherent limitation of this study.
In conclusion, postpartum iliofemoral DVT has a massive thrombus burden with a high rate of IVC involvement and a high incidence of May-Thurner syndrome. Endovascular treatment methods with percutaneous aspiration thrombectomy alone or combined with CDT and iliac vein stenting were rapid and very safe and resulted in a very high rate of thrombus removal and clinical improvement in most patients. However, recurrences, particularly in the first post-intervention month, were very high. The postpartum hormonal state may have been instrumental in this condition. However, if no recurrences occurred in the first post-intervention month, the recurrence rate was low, and there was very good long-term patency of the involved vein. The frequent follow-up of patients in the first post-intervention month is necessary.
